Authors' recommendations: Breast cancer is the most common cancer in the UK. Most women who get breast cancer are over 50 years of age and have already gone through the menopause. There are many types of breast cancer. Buparlisib is a new treatment for one type that is called oestrogen receptor positive, HER2 negative breast cancer, and is for patients whose cancer has continued to grow despite hormone treatments. Buparlisib is given as a tablet taken daily. It is given in combination with fulvestrant, a drug which is injected directly into the muscle, and is already widely used for breast cancer. Both drugs are given twice for the first month of treatment, and then given once a month. Studies at the moment are aiming to show how well these treatments work together and that buparlisib is safe to use. If buparlisib is licenced for use in the UK, it will provide a new treatment option for this patient group.

Project Status: Completed

Year Published: 2016

URL for published report: http://www.hsric.nihr.ac.uk/topics/buparlisib-with-fulvestrant-for-postmenopausal-women-with-metastatic-oestrogen-receptor-positive-her2-negative-breast-cancer-third-line/

English language abstract: An English language summary is available

Publication Type: Not Assigned

Country: England, United Kingdom

Organisation Name: NIHR Horizon Scanning Centre

Contact Address: The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269

Contact Name: c.packer@bham.ac.uk

Contact Email: c.packer@bham.ac.uk

Copyright: NIHR Horizon Scanning Centre (NIHR HSC)